News

A new assessment shows patients younger and older than 40 years both benefit in exacerbation rate and pre-bronchodilator FEV1.

The supplemental new drug application was approved based on results of a phase 3 trial in which IV-to-oral delafloxacin met the primary end point of statistical non-inferiority to moxifloxacin.

The FDA approves Botox injections to treat pediatric patients with both upper and lower limb spasticity, unless it was caused by cerebral palsy.

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

A study comparing the LAMA/LABA to monotherapy found patients without prior ICS treatment benefitted significantly, regardless of disease severity or symptoms.

A comparative cohort found inpatient and outpatient costs, both for respiratory and all-cause conditions, were less per month for patients on the antifibrotic.

New findings from the phase 3 trial show budesonide/ glycopyrrolate/ formoterol fumarate significantly reduces exacerbations among patients with no exacerbation history, compared to dual therapies.

A Cleveland Clinic study showed about 13% of its transfusions were in deference to current guidelines. That said, there's plenty of gray area for cause of care.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

The FDA is allowing Rocket Pharmaceuticals to conduct a global phase I study testing a new treatment approach for Pyruvate Kinase Deficiency.

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

Asthma burden among women can vary based on their age. Are there varying methods of care?

Fewer than 2% of all patients hospitalized with pneumonia in 2014 received the vaccination.

The chronic respiratory disease is often under-diagnosed in female patients.

The newly approved drug is a combination of 3 drugs that target the most common cystic fibrosis mutation.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

AstraZeneca announced approval of the SGLT2 inhibitor for the reduction of hospitalization for heart failure in type 2 diabetes patients in a release on Monday.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.

The drug class has become a mainstay in clinical practice and treatment plans. But could it reach greater, and wider, indications?

Investigators found similar rescue treatment use among patients who do and do not have frequent exacerbations.

A study observing the effect of formulary changes to children with asthma show FEV and FEF scores worsened significantly when switching inhaler types.

The most recent CDC data, presented at CHEST 2019, show nearly 1500 patients have reported an associated lung injury, and 33 have died.

The indication expands the therapy to include newly diagnosed and persistent adults ITP patients who have had an insufficient response to therapy.

How physicians in a shrinking field have taken on a greater burden of leadership roles in patient care.

The US Food and Drug Administration has approved minocycline topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgarism in adults and pediatrics patients 9 years of age or older.

Data from a 961-patient study shows that ustekinumab can induce and maintain remission for patients with moderate-to-severe ulcerative colitis.